Time-saving technologies demonstrate IDEXX’s continued support for today’s busy veterinary professionals
WESTBROOK, Maine, January 13, 2022 /PRNewswire/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced a series of product and service enhancements that allow veterinary practices to be more efficient, while managing increasing volumes of patients. The enhancements provide deeper, actionable insights and personalized support to facilitate faster, safer clinical decisions.
Veterinary professionals are more than ever faced with time constraints. People spending more time at home throughout 2020 has led to increased pet adoptions and a stronger human-animal bond. Today’s pet parents pay more attention to the health of their pets, which further increases the number of practice cases. These factors combined with the added rigor of pandemic protocols have intensified the busy schedules of today’s veterinary professionals.
Understanding these current challenges, IDEXX demonstrates its continued support for the industry through the following product enhancements that help veterinarians save time, while improving the lives of pets:
IDEXX 4Dx® Plus Test Now Offers Clinical Decision Support to help veterinarians interpret results from reference or in-house laboratories more quickly. Following a positive result, clinical decision support on VetConnect® PLUS provides follow-up considerations, as well as patient-specific interpretive assistance, to help veterinarians identify signs of active infection and more quickly determine next steps. Additionally, enhancements to the SNAP 4Dx® More Testing are planned in the first half, including increased sensitivity for Anaplasma and extended storage at room temperature that will help save staff time.
Vet Connect® PLUS Mobile App has recently been upgraded to provide on-the-go veterinary professionals with all the patient information they need in the palm of their hand, faster than ever. Updates include simplified case management, easier-to-read reports, and more intuitive navigation, all available in multiple languages, allowing vets to spend less time researching information and more time with patients.
SediVue Dx® Urine Sediment Analyzer Now Features Neural Network 6.0—the latest version of the analyzer’s advanced algorithmic software powered by 800 million urine sediment images. This release increases the sensitivity of bacteria, helping veterinarians more quickly determine the presence of a urinary tract infection. Additionally, new interpretive commentaries will be available in early spring, providing clinical information and support to help veterinarians move forward with more confidence.
New catalyst® SDMA Test, the early indicator of a decline in kidney function, features innovative new technology that brings reagents to the edge of the slide, allowing it to be run more efficiently as part of routine chemical profiles. Available from mid-year, this enhancement will save busy practices time by eliminating steps and streamlining workflows, facilitating faster delivery of results.
“At IDEXX, we are committed to providing clarity for veterinarians as they manage the increasing demands on their services,” said Jay Mazelsky, President and CEO of IDEXX. “Inspired by customer needs and delivered through innovation, these enhancements enable practice efficiency and support veterinarians with actionable insights that drive more confident clinical decisions.
For more information about IDEXX products and services, visit idexx.com.
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that provide solutions and information to practicing veterinarians around the world. IDEXX products enhance veterinarians’ ability to provide advanced medical care, improve staff efficiency and create more cost-effective practices. IDEXX is also a global leader in providing diagnostic testing and information for livestock and poultry, testing for water and milk quality and safety, and point-of-care and laboratory diagnostics. for human medicine. Based at Maine, IDEXX employs approximately 9,800 people and provides products to customers in more than 175 countries. For media inquiries, please contact us at [email protected]
Note Regarding Forward-Looking Statements
This press release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects”, “may”, ” anticipates’, ‘intends’, ‘would’, ‘will’, ‘plans’, ‘believes’, ‘estimates’, ‘should’, ‘plans’ and similar words and expressions. These forward-looking statements are intended to provide our current expectations or predictions of future events; are based on current estimates, projections, beliefs and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to important risks, uncertainties, assumptions and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. Statements filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX undertakes no obligation and expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are encouraged to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available in the SEC’s EDGAR database at sec.gov and through IDEXX’s website at idexx. com).
Show original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-innovative-diagnostic-and-software-solutions-provide-workflow-efficiency-and-faster-more-confident-clinical-decisions-301459620.html
SOURCE Idexx Laboratories, Inc.